Arctic Therapeutics Announces Enrollment of First Patients in Phase IIa Trial of AT-004 for Acne Vulgaris

Contributed by: PR Newswire

Tags

AT-AT-004-IIa-Trial

More Like This

Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer's Disease

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

ACCESSWIRE associated0

GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting